EP News: Basic and Translational

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a hereditary arrhythmia syndrome. Mutations in ryanodine receptor type 2 (RYR2) are responsible for ≈60% of cases of CPVT. In the present study, Pan et al (Circ Res 2018;123:953, PMID 30355031) tested whether in vivo genome editing using the CRISPR/Cas9 system could correct CPVT in mice heterozygous for RyR2 mutation R176Q (R176Q/+). Guide RNAs were designed to disrupt the mutant allele in the neonatal R176Q/+ mice with the SaCas9 (Staphylococcus aureus Cas9) genome editing system using a single subcutaneous injection of adeno-associated virus serotype 9.
Source: Heart Rhythm - Category: Cardiology Authors: Tags: EP NEWS Source Type: research